CombiMatrix Forms Scientific Advisory Board; Includes Leaders in Reproductive Health, Pathology, Genetics, Molecular Biology ...
March 09 2016 - 6:46PM
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for prenatal and
postnatal developmental disorders and pre-implantation genetic
screening services, announces the formation of a Scientific
Advisory Board to support further adoption of the Company’s
molecular diagnostic tests, identify and evaluate new market
opportunities and consult on health care policies, among other
activities.
“We are privileged to have this group of five
esteemed practicing physicians and academic leaders to bring fresh
perspectives to our business strategy and to enhance our industry
standing,” said Mark McDonough, President and Chief Executive
Officer of CombiMatrix. “We continue to gain traction in the in
vitro fertilization and miscarriage analysis markets as evidenced
by 33% growth in reproductive health revenues for the most recent
quarter. We will look to our Scientific Advisory Board for
strategies to maximize our market presence and seek guidance in
identifying and evaluating new technologies to expand our test
portfolio and leverage our sales infrastructure.”
Members of CombiMatrix’s Scientific Advisory Board
are as follows:
- Brian D. Acacio, MD, is Medical Director and
Founder of the Acacio Fertility Center in Laguna Niguel, Calif.,
which specializes in reproductive endocrinology, and has been a
practicing OB/GYN for 23 years. He is a fellow of the
American College of Obstetricians and Gynecologists and Pacific
Coast OB/GYN Society, and member of the American Society for
Reproductive Medicine and Pacific Coast Reproductive Society.
He has authored numerous peer-reviewed journal articles and
received multiple awards including the 2014 Vitals.com “Patient’s
Choice Award.” Dr. Acacio graduated from Georgetown
University School of Medicine and completed his residency at LAC +
USC Medical Center.
- Matthew C. Goering, PhD, HCLD, is Director of
Clinical Embryology at the Center for Advanced Reproductive
Medicine at the University of Kansas and Assistant Professor at the
University of Kansas Department of Obstetrics and Gynecology
Division of Reproductive Endocrinology and Infertility. He
serves as a clinical consultant on in vitro fertilization and
embryology for several laboratories. Dr. Goering is a member
of the American Society for Reproductive Medicine, American
Association of Bioanalysts and American Society of Human
Genetics. He received a BS in biology and chemistry from
Bethel College and a doctorate in molecular biology from the
University of Kansas School of Medicine.
- Lee P. Shulman, MD, FACOG, FACMG, is the Anna
Ross Lapham Professor in Obstetrics and Gynecology and Chief of the
Division of Reproductive Medicine at Northwestern University,
practices at Northwestern Medical Facility Foundation and is
affiliated with Northwestern Memorial Hospital. He
specializes in clinical genetics and has been a practicing OB/GYN
for 32 years. Dr. Shulman is a member of numerous professional
societies and associations and has received numerous professional
awards. He is executive editor of the Journal of Gynecologic
Surgery and consultant editor for The Journal of Reproductive
Medicine, and serves on the editorial boards of 16 peer-reviewed
journals. He has authored more than 200 abstracts and more
than 150 articles published in peer-reviewed journals. Dr. Shulman
graduated from Weill Cornell Medical College and completed a
residency at North Shore University Hospital.
- Thomas Westover, MD, FACOG, is an Assistant
Professor of Maternal Fetal Medicine and Obstetrics/Gynecology at
Cooper Medical School, Rowan University in Camden, NJ. He is former
President of the NJ Society of Maternal Fetal Medicine, the current
Vice Chair of the NJ Section of the American College of ObG, the
Co-Chair of the NJ Hospital Association Statewide Perinatal Safety
Collaborative and a member of the ACOG District 3 Advisory Council.
Dr. Westover graduated from the University of Medicine and
Dentistry of New Jersey, NJ Medical School in Newark, NJ, and
completed a residency in Obstetrics/Gynecology and fellowship in
Maternal Fetal Medicine at UMDNJ, Robert Wood Johnson Medical
School, New Brunswick, NJ.Dr. Westover noted ACOG’s statement in
Practice Bulletin #102 that the “most important components of a
stillbirth examination are fetal autopsy, karyotype and placenta
examination,” and further that the NICHD Stillbirth Collaborative
Research Network published in the New England Journal of Medicine
that microarray testing of stillbirths, such as the test
offered by CombiMatrix, was more likely than traditional karyotype
to provide a genetic result and was better at detecting genetic
abnormalities when aneuploidy is present.
- Mandolin S. Ziadie, MD, specializes in
pediatric and perinatal pathology, is Director of Placental
Pathology at Memorial Regional Hospital in Hollywood, Fla., and is
affiliated with the Joe DiMaggio Children’s Hospital. Dr.
Ziadie has authored multiple research articles, reviews and
editorials on obstetrics and gynecology published in peer-reviewed
journals. She graduated from the University of Miami School
of Medicine, completed her residency in anatomic and clinical
pathology at the University of Texas Southwestern Medical Center
and her fellowship in pediatric pathology at Children’s Medical
Center of the University of Texas Southwestern Medical Center.
About
CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular
diagnostic solutions and comprehensive clinical support to foster
the highest quality in patient care. CombiMatrix specializes in
prenatal diagnostics, miscarriage analysis for recurrent pregnancy
loss, pediatric genetics and pre-implantation genetic screening,
offering DNA-based testing for the detection of genetic
abnormalities beyond what can be identified through traditional
methodologies. CombiMatrix performs genetic testing utilizing a
variety of advanced cytogenomic techniques, including chromosomal
microarray, standardized and customized fluorescence in situ
hybridization (FISH) and high-resolution karyotyping. CombiMatrix
is dedicated to providing high-level clinical support for
healthcare professionals in order to help them incorporate the
results of complex genetic testing into patient-centered medical
decision making. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations, speak only as
of the date hereof and are subject to change. All statements, other
than statements of historical fact included in this press release,
are forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not
limited to, statements regarding projected results of operations
and management's future business, operational and strategic plans,
recruiting efforts and test menu expansion. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties referred
to above include, but are not limited to: our ability to open new
market opportunities for our tests; our ability to drive scientific
advancement; our ability to successfully expand the base of our
customers and strategic partners, add to the menu of our diagnostic
tests, develop and introduce new tests and related reports, expand
and improve our current suite of services, optimize the
reimbursements received for our microarray testing services, and
increase operating margins by improving overall productivity and
expanding sales volumes; our ability to successfully accelerate
sales, steadily increase the size of our customer rosters in both
prenatal and developmental genetic testing markets; our
ability to attract and retain a qualified sales force in wider
geographies; our ability to ramp production from our sales force
and our strategic partners; rapid technological change in our
markets; changes in demand for our future services; legislative,
regulatory and competitive developments; the outcome of pending
litigation; general economic conditions; and various other factors.
Further information on potential factors that could affect our
financial results is included in our Annual Report on Form 10-K,
Quarterly Reports of Form 10-Q, and in other filings with
the Securities and Exchange Commission. We undertake no
obligation to revise or update publicly any forward-looking
statements for any reason, except as required by law.
Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Investor Relations Contact:
LHA
Jody Cain
(310) 691-7100
jcain@lhai.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Jul 2023 to Jul 2024